Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagill…

Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in ...
Contract Pharma

Modified Release Tablets: Strategies for Optimising Drug Delivery

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

$7.12 Bn Nutraceutical Excipients Market by Source, Functionality, End Product, Formulation, Functionality Application and Region - Global Forecast to 2030

The nutraceutical excipients market is projected to rise from USD 4.98 billion in 2025 to USD 7.12 billion by 2030, expanding ...

The cost of a tablet

Exploring the vital link between healthcare costs and patient affordability in India's evolving medical landscape.

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilitiesThe ...
Contract Pharma

Piramal Pharma Solutions Introduces Tablet-in-Capsule Drug Delivery System

Piramal Pharma Solutions has introduced a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad, India.
Managing Intellectual Property

CNIPA sides with generic drug maker in dispute over mirogabalin besylate tablets

Yue Guan of Wanhuida Intellectual Property explains how the CNIPA’s rulings on mirogabalin besylate tablets highlight the importance of formulation patent drafting and claim amendments in China’s drug ...

Zydus receives USFDA tentative approval for Dapagliflozin Tablets

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga Tablets, 5 mg and 10 mg).

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Tablets to gummies: How traditional medicines like shilajit, ashwagandha are getting a makeover

Ayurveda is transitioning from tradition to evidence, driven by policy, science, and innovation. With global recognition, clinical trials, standardised extracts, and AI-guided research, ancient remedi ...